Phio signs cGMP manufacturing deal; PH-762 Phase 1b shows 85% pathological response

Phio Pharmaceuticals Corp.

Entered cGMP drug product manufacturing agreement with U.S. manufacturer for clinical and commercial supply of PH-762.
PH-762 Phase 1b trial: 22 patients completed, no dose-limiting toxicities or serious adverse events.
Pathological response rate across all cohorts ~65%; highest-dose cohort achieved 85% (6 of 7 patients).
FDA engagement for next-stage clinical development targeted for Q2 2026.
Cash and equivalents projected to sustain operations into H1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.